SLO induces eukaryotic cell lysis, resists neutrophil phagocytosis and clearance of GAS, inhibits neutrophil oxidative burst, and blocks neutrophil degranulation, interleukin-8 secretion, and reactivity, thereby contributing to the pathogenesis of streptococcal infection (Uchiyama et al., 2015), and thus has increasingly becoming a promising potential drug target for the treatment of streptococcal infection (Arzanlou and Bohlooli, 2010; Turner et al., 2020). This evidence concerns the gene KCNMA1 and streptococcal infection.